Most patients treated for cardiovascular disease have a BMI of at least 27, suggesting that many patients could benefit from semaglutide regardless of their starting weight
Direct and Indirect Effects of GLP-1 and GIP Receptor Agonism in the Human Body 2,4,5,12 In addition to their beneficial actions in diabetes and obesity, new research suggests that incretin-based therapies may reduce inflammation in the heart, liver, kidneys, and brain
No published protocols
Switching from Semaglutide to Tirzepatide dosage should only be done under medical supervision to ensure a safe transition
GLP-1 receptor agonists also slow gastric emptying, prolonging the sensation of fullness after meals and reducing postprandial glucose excursions
Furthermore, adipose tissue (body fat) is biologically active and secretes pro-inflammatory cytokines